Lupin Limited announces satisfactory FDA inspection results for Mandideep facility
Global pharmaceutical major, Lupin Limited (Lupin), has announced receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Mandideep Unit-2 manufacturing facility. This report, indicating a significant milestone, was issued following the facility’s recent inspection, held from August 7 to August 11, 2023. Remarkably, the inspection concluded […]